{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:03:04Z","timestamp":1790694184765,"version":"4.1.0"},"reference-count":28,"publisher":"Wiley","issue":"16","license":[{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>In the last decade, melanoma treatment has improved significantly. However, data on population\u2010level treatment utilization and survival trends among older patients is limited. This study aimed to analyze trends in systemic anticancer therapy (Rx), including the uptake of immune checkpoint inhibitors (ICIs), in conjunction with trends in cause\u2010specific survival among older patients (66+) diagnosed with advanced melanoma (2008\u20132019).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used the Surveillance, Epidemiology, and End Results (SEER)\u2010Medicare Condensed Resource to assess any Rx utilization among patients first diagnosed with advanced melanoma in 2008\u20132010, 2011\u20132014, and 2015\u20132019, stratified by stage, and type of first\u2010line Rx among patients receiving Rx. The SEER dataset was used to evaluate trends in cause\u2010specific survival by year of diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Rx utilization (any type) almost doubled, from 28.6% (2008\u20132010) to 55.4% (2015\u20132019) for stage 3 melanoma, and from 35.5% to 68.0% for stage 4 melanoma. In 2008\u20132010, the standard first\u2010line treatment was cytokines\/cytotoxic chemotherapy\/other. By 2015\u20132019, only 5.1% (stage 3) and &lt;3.6% (stage 4) of patients receiving Rx received these agents, as ICIs emerged as the dominant treatment. Both 1\u2010year and 5\u2010year cause\u2010specific survival significantly improved since 2010 for stage 4 and since 2013 for stage 3.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study shows a significant rise in Rx utilization and a rapid transition from cytokines\/cytotoxic chemotherapy to ICIs, reflecting a rapid uptake of highly effective treatment in a previously challenging disease with limited options before 2011. The documented survival improvement aligns with the adoption of these novel treatments, underscoring their significant impact on real\u2010world patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.70131","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T09:25:30Z","timestamp":1724837130000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evolving patterns in systemic treatment utilization and survival among older patients with advanced cutaneous melanoma"],"prefix":"10.1002","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9548-5770","authenticated-orcid":false,"given":"Yoon Duk","family":"Hong","sequence":"first","affiliation":[{"name":"Division of Cancer Control and Population Sciences National Cancer Institute  Bethesda Maryland USA"},{"name":"Kelly Services, Inc.  Rockville Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Enewold","sequence":"additional","affiliation":[{"name":"Division of Cancer Control and Population Sciences National Cancer Institute  Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Sharon","sequence":"additional","affiliation":[{"name":"Division of Cancer Treatment &amp; Diagnosis National Cancer Institute  Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy L.","family":"Warner","sequence":"additional","affiliation":[{"name":"Lifespan Cancer Institute, Rhode Island Hospital  Providence Rhode Island USA"},{"name":"Center for Clinical Cancer Informatics and Data Science, Legorreta Cancer Center Brown University  Providence Rhode Island USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8141-9249","authenticated-orcid":false,"given":"Amy J.","family":"Davidoff","sequence":"additional","affiliation":[{"name":"Division of Cancer Control and Population Sciences National Cancer Institute  Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Zeruto","sequence":"additional","affiliation":[{"name":"Information Management Services, Inc.  Calverton Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela B.","family":"Mariotto","sequence":"additional","affiliation":[{"name":"Division of Cancer Control and Population Sciences National Cancer Institute  Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0253"},{"issue":"1","key":"e_1_2_11_3_1","first-page":"21","article-title":"Dacarbazine\u2010based chemotherapy for metastatic melanoma: thirty\u2010year experience overview","volume":"19","author":"Serrone L","year":"2000","journal-title":"J Exp Clin Cancer Res"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.7567"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1159\/000351499"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/315609"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.706"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5630"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.21873\/ANTICANRES.12536"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000264"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/JAMANETWORKOPEN.2020.15656"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024782"},{"key":"e_1_2_11_13_1","unstructured":"National Cancer Institute.Division of Cancer Control & Population Sciences. SEER\u2010Medicare Linked Data Resource. Accessed August 18 2022.https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/"},{"key":"e_1_2_11_14_1","unstructured":"National Cancer Institute.Division of Cancer Control & Population Sciences. SEER\u2010Medicare Summarized Data. Accessed June 6 2024.https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/medicare\/summarized\u2010data.html"},{"key":"e_1_2_11_15_1","unstructured":"National Cancer Institute.NCI Comorbidity Index Overview. Accessed October 24 2022.https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/considerations\/comorbidity.html"},{"key":"e_1_2_11_16_1","unstructured":"National Cancer Institute.Surveillance Epidemiology and End Results Program. SEER*Stat Software. Accessed November 21 2023.https:\/\/seer.cancer.gov\/seerstat\/"},{"key":"e_1_2_11_17_1","unstructured":"National Cancer Institute.Division of Cancer Control & Population Sciences. Surveillance Research Program JPSurv. Accessed November 21 2023.https:\/\/analysistools.cancer.gov\/jpsurv\/"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-21-0423"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu540"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/93.11.850"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-010-9644-7"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.3049"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.6489"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/CNCR.20982"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01763"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.22.2720"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199912303412706"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.010"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.70131","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.70131","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.70131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:49:09Z","timestamp":1790693349000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.70131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":28,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1002\/cam4.70131"],"URL":"https:\/\/doi.org\/10.1002\/cam4.70131","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"2024-01-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70131"}}